Pattern of care and post-progression survival in recurrent GBM after TMZ-based chemoradiation

被引：0
|
作者：
Kim, D. [1 ,2 ]
Lee, J. H. [2 ,3 ]
Yoon, H. I. [4 ]
Kim, N. [5 ]
Lim, D. H. [5 ]
Song, J. H. [6 ]
Wee, C. W. [3 ,7 ]
Kim, I. A. [3 ,8 ]
机构：
[1] Seoul Natl Univ, Coll Med, Radiat Oncol, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Radiat Oncol, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Radiat Oncol, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Radiat Oncol, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Catholic Univ, Seoul St Marys Hosp, Coll Med, Radiat Oncol, Seoul, South Korea
[7] SMG SNU Boramae Med Ctr, Radiat Oncol, Seoul, South Korea
[8] Seoul Natl Univ, Bundang Hosp, Radiat Oncol, Seongnam, South Korea
来源：
RADIOTHERAPY AND ONCOLOGY | 2023年 / 182卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-1128
引用
收藏
页码：S902 / S902
页数：1
相关论文
共 42 条
  • [1] DOES TIME TO FIRST PROGRESSION (TTP) IMPACT POST-PROGRESSION SURVIVAL IN GLIOBLASTOMA (GBM) IN THE TEMOZOLOMIDE (TMZ) TREATMENT ERA?
    McNamara, Mairead G.
    Lwin, Zarnie
    Jiang, Haiyan
    Chung, Caroline
    Millar, Barbara-Ann
    Sahgal, Arjun
    Laperriere, Normand
    Mason, Warren P.
    NEURO-ONCOLOGY, 2013, 15 : 120 - 120
  • [2] The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT
    Manuel de la Torre-Aláez
    Carlota Jordán-Iborra
    Andrea Casadei-Gardini
    José Ignacio Bilbao
    Macarena Rodriguez-Fraile
    Lidia Sancho
    Delia D’Avola
    José Ignacio Herrero
    Mercedes Iñarrairaegui
    Bruno Sangro
    CardioVascular and Interventional Radiology, 2020, 43 : 1165 - 1172
  • [3] The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT
    de la Torre-Alaez, Manuel
    Jordan-Iborra, Carlota
    Casadei-Gardini, Andrea
    Bilbao, Jose Ignacio
    Rodriguez-Fraile, Macarena
    Sancho, Lidia
    D'Avola, Delia
    Herrero, Jose Ignacio
    Inarrairaegui, Mercedes
    Sangro, Bruno
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2020, 43 (08) : 1165 - 1172
  • [4] Pattern of progression determines post-progression survival in patients with hepatocellular carcinoma treated with Radioembolization
    Jordan, C.
    de la Torre, M.
    Gardini, A. C.
    Bilbao, J. I.
    Rodriguez-Fraile, M.
    Rodriguez, L. S.
    D'avola, D.
    Inarrairaegui, M.
    Herrero, J. I.
    Quiroga, J.
    Sangro, B.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S13 - S13
  • [5] EVALUATION OF POST-PROGRESSION TREATMENTS AFTER VAL-083 IN RECURRENT AND NEWLY DIAGNOSED GBM MGMT-UNMETHYLATED PATIENTS
    Kamiya-Matsuoka, Carlos
    Weathers, Shiao-Pei
    Yung, W. K. Alfred
    Loghin, Monica
    Majd, Nazanin
    Brown, Dennis
    Langlands, John
    Schwartz, Richard
    Knight, Stephanie
    Puduvalli, Vinay
    de Groot, John
    O'Brien, Barbara
    NEURO-ONCOLOGY, 2023, 25
  • [6] Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma
    Kobayashi, Satoshi
    Fukushima, Taito
    Ueno, Makoto
    Chuma, Makoto
    Numata, Kazushi
    Tsuruya, Kota
    Arase, Yoshitaka
    Hirose, Shunji
    Kagawa, Tatehiro
    Hattori, Nobuhiro
    Watanabe, Tsunamasa
    Matsunaga, Kotaro
    Uojima, Haruki
    Hidaka, Hisashi
    Kusano, Chika
    Morimoto, Manabu
    Maeda, Shin
    LIVER INTERNATIONAL, 2024, 44 (06) : 1343 - 1350
  • [7] POST-PROGRESSION SURVIVAL AFTER ERLOTINIB TREATMENT IN PATIENTS WITH ADVANCED NSCLC
    Trojniak, M. P.
    Palozzo, A. C.
    Imbevaro, S.
    Rescigno, P.
    Pastorelli, D.
    Jirillo, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 439 - 439
  • [8] The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer
    Yanazume, Shintaro
    Ushiwaka, Takashi
    Fukuda, Mika
    Togami, Shinichi
    Kamio, Masaki
    Kobayashi, Hiroaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (09) : 1407 - 1415
  • [9] Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
    Kobayashi, Satoshi
    Fukushima, Taito
    Ueno, Makoto
    Chuma, Makoto
    Numata, Kazushi
    Tsuruya, Kota
    Arase, Yoshitaka
    Hirose, Shunji
    Kagawa, Tatehiro
    Hattori, Nobuhiro
    Watanabe, Tsunemasa
    Matsunaga, Kotaro
    Uojima, Haruki
    Hidaka, Hisashi
    Kusano, Chika
    Morimoto, Manabu
    Maeda, Shin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 539 - 539
  • [10] SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])
    Cloughesy, Tim
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Hoang-Xuan, Khe
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Revil, Cedric
    Abrey, Lauren
    Chinot, Olivier L.
    NEURO-ONCOLOGY, 2014, 16
12345